Medigen Biotechnology Corp. (TPEX:3176)
36.50
+1.75 (5.04%)
Sep 8, 2026, 1:30 PM CST
Medigen Biotechnology Revenue
Medigen Biotechnology had revenue of 284.74M TWD in the quarter ending June 30, 2026, a decrease of -21.08%. This brings the company's revenue in the last twelve months to 1.27B, down -22.05% year-over-year. In the year 2025, Medigen Biotechnology had annual revenue of 1.58B with 15.28% growth.
Revenue (ttm)
1.27B
Revenue Growth
-22.05%
P/S Ratio
3.82
Revenue / Employee
n/a
Employees
n/a
Market Cap
4.84B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.58B | 209.80M | 15.28% |
| Dec 31, 2024 | 1.37B | 214.98M | 18.57% |
| Dec 31, 2023 | 1.16B | 101.77M | 9.64% |
| Dec 31, 2022 | 1.06B | -2.87B | -73.08% |
| Dec 31, 2021 | 3.92B | 3.31B | 537.17% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sinphar Pharmaceutical | 3.45B |
| Savior Lifetec | 1.12B |
| Mycenax Biotech | 815.87M |
| TaiGen Biopharmaceuticals Holdings | 256.46M |
| Pharmosa Biopharm | 53.38M |
| Formosa Pharmaceuticals | 52.59M |
| UnicoCell Biomed | 22.46M |
| Great Novel Therapeutics Biotech & Medicals | 6.21M |